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Abstract
Pharmacogeoom1CS, the fusion of pharmacology and genomics, shows
strong potential to solve many of today's dosing problems. lnter-µlllent
dosing requirements, mainly due to genetic variability between paltents,
represent significant challenges for prescribe rs. Certain receptors, drugtargeted protems, drug-transix>rt mechanisms and drug-metaoofizing
enzymes are genetJcally established. Hence, anydefect, atsence or
abnormality in the gene could alter how an affected individual will resix>rxl
to a given drug. Due to advancements 1n technology, heafth care professt0nals who uttlize phatmacogeno111CS may assess a patient's genetlC
profile arxl detennine a predrcted resJX>nse to specific med1cat1ons. This
may resul11n ix>tentially opt1mal dosing at Iha onset or treatment rather
than going through a tnal-and-error process that could take many months.
Despite the recent devebpments n pharmacogenom1cs, several oorriers
must be crossed before the benefcs of 1ndwidualized medicine can be
fully appreciated and wKlespread. Some of these oo.rriers involve limned
knowledge, tesung and heated ethcaJ debates. This article provides an
overview of phannacogeoomJCS for the pharmac1St.

reactions ranked high in the top causes of preventable death, personalized
medicme may decrease the number of occurrences and save fives. This
concept of lndiv1duafized drug therapy may be realized with the use of
phannacogenomics. In fact, the FDA endorses the applica!Jon of this field
as evidenced with a recent change to the product labeling for the aoove
mentioned drug, cfopidogrel. It now contains a black oox warning (Figure 1):

The basics of pharmacogenomics
Pharmacogenom1cs IS the fusion of pharmacology and genomtCS. 2
Pharmacogenom1cs re fers to the general study of all of the many d1f·
ferem genes that determine drug behavior. Pharmacogenencs refers
to the study of inherited differences (vanation) 1n drug metaoohsm and
response. Although these two disc1p1tnes are different, the dist1nct10n
between them is considered arbitrary by many researchers. Currantly, 11
1s not unusual for the two terms to be used interchangeably.'
Certain receptors , drug targeted proteins, drug transport mechanisms
and drug metabolizing enzymes are based on a person's genellc code,
thus, 1t can be concluded that any defect, absence or abnonnaijty in the
gene has the potential to alter how an affected individual will respond to
Introduction
certain drugs.4 The genes most commonly studied are those that code
One size fits all. In drug therapy, this 1s rarely true but, unfortunately, 1t
for enzymes that metabolize drugs; these enzymes affect the drug's
is often the approach used when treating patients. If the initial dose is
pharmacokinetic and pharmacodynamic properties.
suooptimal, then the dose is adjusted. For example, clopidogrel is an
The alteration of the gene is typically the result of a single nucleotide
oral antiplatelet drug that is typically initiated at a dose of 75mg once
1
polymorphism
(SNP).5 SNPs are DNA sequence variations that occur
daily. The effectiveness of this drug depends on its activation to an acwhen
a
single
nucleotide
base in the gene sequence is altered. A SNP
tive merabotrre t:ly !he cytochrome P450 (GYP) syscem. Paaencs who are
within
a
gene
has
the
potential
to cause a m15sense, sense or nonsense
"poor meraboltzers" may experience a thromboembolic event due to sub-polymorphism
in
the
protein
1t
codes
for. A mtSsense polymorphism results
therapeutic levels of acuve drug before the drug ts appropriately dosed.
1n
a
code
for
a
different
amino
acid
than
the unaltered gene. A sense
Conversely, patients who are rapid metabolizers of clop1dogref may have
polymorphism results in tile same amino acid as intended, but by a differincreased levels of acbve drug and experience adverse bleeding events.
ent sequence. A oonsense polymorphism results 1n the earty termination
This trial-and-error dosing tandem will likely con tinue until the opumal
of the protein synthesis. SNPs are among the top geneoc vanalJOns being
therapy 1s ach10ved or alternate treatment is prescnbed. This delay in
examined today because a single SNP within a gene can alter protein
appropnate treatment may result In undesirable consequences for the
express ton of such enzymes as cytochrome P450 (CYP} metaooltzing
patient and increased health care costs. What tf tl1ere was a way co stop
enzymes.
this cycle and effectively treat the patient the first time?
Clinicians can take advantage of a patienrs genellc profile to fit
New technological advances have the ix>tential to aid health care
their
specific needs at the onset of treatment rather than go through a
providers in selection of appropriate drugs and dosage regimens personaltrial-and-error
process that can take many months. Notonfy does this
ized for individual patients. In additi:>n, this new technology may predict
save
time
and
money, but pharmacogenomics can also prevent many
patients likely to experience adverse drug reactions. With adverse drug
adverse drug reactions. Adverse drug reactions are among
the leading causes of death in £he United States.' Many
WARNING: DIMINISHED EFFECTIVENESS TN POOR METABOLIZERS
drugs can elicit an adverse reactton in some patients and
• Effectiveness of Plavix® depends on activation to an active metaboltu by 1he
nor in others. Consequently, it 1s important to screen a pacytochrome P4SO (CYP) systfm. pnnc1pally CYP2Cl9 .
tienrs genetic profile before selecnng a potentially dangerous medication. The utilization of pharmacogenomics has
• Poor metabohzers treat.ed with Plav1x® at re~ommended doses e:dul111 lugher
cardiovascular event rates followmg acute coronary syndrome (ACS) or percutaneous
the potential to slgnrflcantly lower the inctdence of adverse
coronary mte:rvenuon (PCl) than pal!ents W1tl1 nonnal CYP1C 19 funcboo
reactJons.7
Test• are avalable to 1denufy a pauenl' s CYP2C l 9 genotype and can be used as an aid
detemurung lherapeuuc strategy

Ill

Figure 1: Plavix® {clopidigrel) Black Box Warning'
Ada.~ed from products.sanoli-aventis.us/plavix/pavix.html
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Pharmacogenomics: Past
The firs t use of pharmacogenomic technology was m 1932
when the ability to taste phenylthiocarbamide was tested and evaluated. 7
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It had been observed that some populations had the ability to taste the
compound, while others did not. Those 1dent1fled as being unable to
taste the chemical compound were autosomal recessive (did not code)
for the enzyme that enabled them to taste the compound. Through thlS
study, researchers concluded that genetic makeup determined how an
individual would respond to certain chemicals or drugs.
During U111 1940s and 1950s, S!.;11111Lists began mv11sligating the rnechanisms and impact of cytochrome P450 on the metabolism of drugs. It
came to the attention of some scientists when they noticed that some
patients taking the antihypertensive medication debrisoquine had an
enormous decrease in blood pressure.2 Through further studies , it was
determined that the specific population experiencing this effect had two
recessive alleles coding forthe enzyme responsible for metabolizing the
medication. The lack of metabolizing enzyme caused an exacerOO.tion
of the drug's effects due roan accumulation 1n the body.2 This discovery
further supported what researchers had hypo thesized in the 1930s. The
extent to which a drug is metabolized is highly influenced by a person's
genetics.

for experiencing a hypersensitivity reaction. Prior to ininating therapy
with abacavir, screening for the allele 1s recommended. This approach
has been found to decrease Lhe nsk of hypersens1t1V1ty reactton. HLA·
8'5701-negative patients may develop a suspected hypersensitJv1ty
reacoon to abacavir. however, this occurs sign~icantly less frequently
than in HLA-8'5701-positive patients. 10
Anothe1 e11zy1111:1 c11t111d TPMT (lt1iuµurine 111ethylll1:111slerase) µlays a11
important role in metabolizing thiopurines. A small percentage of cauca·
sians have genetic variants that prevent them from producing an active
form of this protein. As a result, thiopurines elevate to toxic levels in the
patient because the inactive form of TMPT is unable to break down the
drug. Today , thiopurine methyltransferase genotyping and thiopurine
metabolite testing 11ave been established as an adj.met to monitoring
patients taking thiopurine drugs such as azathioprine.11

• Wartarin (Coumadin®) CYP 2C9
· Clopidogrel (Plav!X®): CYP 2C 19

Pharmacogenomics: Future
ThOugh pharmacogenom1cs is considered to be in rrs infancy, many
researchers and health care professionals anbc1pate significant benefits
from 1t:s use in the future (Table 2). More indiv<luahzed medicines will
be developed based on t11e proteins, enzymes, and RNA molecules associated wrth genes and diseases. Instead of \he standard rnal·and-error
method of matching patients with the right dru~s. chmc1ans will be able
to analyze a patienrs genetic profile and prescnbe optlmal drug therapy
and dose from the initiation of treatment
Pharmacogenomics may result in advanced screening for disease,
allowing a person to make adequate lifestyle and environmental changes
at an early age so as to avoid or lessen the severity of a genetic disease.
Better vaccines,2 improvements in the drug discovery and approval process.' and a decrease in the overall cost of health care are all foreseeable
results of pharmacogenomics technology.

• Azathiopine (lmurar®): thioµ.irire melhyltransferase
• 6-MlrcaJXopurine (Punnethol®)· thiopurine methyltransferase

Table 2: Future Benefits ot Pharmacogenomics

Pharmacogenomics: Today
Currently, !he official product labeling in more than 20 medicatJOns now
mention the availability of tests for genetic variations that impact the
drug's action (Table 1). However, tes ting is optional. The Clinical Tnals
Web site notes that 365 pharmacogenomic studies are being conducted
throughout !he world. 2
Table 1: Examples of Current Drugs with Pharmacogenomic Parameters

• lrinotecan (CamJXosar®} UGTIA 1'28 horrozygosny
· 5-Flurouractl (8t.dex®): D1hydroPfrim1d1ne dehydrogenase

· Optimal drug therapy lromthe inn1ation of treatment
• M:>re accurate methods of determining appro~1e drug chsages
· Advanced screening for disease

• Aoocavir HLA·B'5701
A specific example of hew phannacogenomics can be used today iS
genetic analystS of CYP2C9 to ass st with warfarin dosing. As mentJOned
prevtously, SNPs are among the top genetic variations being examined
today because a single SNP withrn a gene can alter protein expresston
of enzymes such as cytochrome P450 (CYP) metabolizing enzymes. A
commonly mutated, clinically significant CYP enzyme is CYP2C9. Instead
of initiating a patient on a standard dose, determination of the patienrs
genetic profile allows the clinician to determine a more appropriate dose
from the start The ratJOnale behind this lies within the CYP2C9 allele. The
role of CYP2C9 is to metaboltze the S enantiomer to its inactive metabolites. If a panent has a polymorphism within their CYP2C9 allele, they will
have an increased nsk of bleeding This is due to a slower metabolism,
which allows the drug to stay in the body longer and increase its effects.
Through the use of pharmacogenomics, an adjusted dose can be 1nibated
before the paoont even leaves the ohyslc1an·s office, thereby avoiding the
extra ome wamng for an INR (international normalized rauo) to return and
potenually averong a bieed. 9
A black box warning suggesting pharmacogenomic testmg 1s part
ul U111 FDA-required labeling ro1 Uie antiviral agenl abacavi1. 111 lhis
example, patients with a specific allele (HLA·B'5701) are at high nsk

· Vaccines
• Improvements in the drug d1Scovery and approval process
• Decrease in the overa II cost of health care
Ada JXed from: http/ lwww.ornl.gov/sci/techresourceslHurran_Gerome/medicine/
~.shtml

Challenges of pharmacogenomics
Despite the recent developments in pharmacogenomics, several barriers
must be crossed before the benefits of personalized medicine can be
fully appreciated. Due to the frequency of SNPs, millions must be identified and analyzed to determine their involvement in drug response. To
further complicate this process, researchers sull have limned knowledge
of which genes are involved with each drug response Moreover, several
genes are likely to influence drug response. creaong an exuemely
ume~ nsummg and complicated path of study '2 Although technological
advances have led to tests that can identify multiple localions or genes
on chromosomes 1n a short time, the availability of such tests limits
their application in patient care. Only a very small percentage of U.S.
laboratones offer pharmacogenetic testing, and often they are located
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a considerable distance away from the patient. This results in a lengthy
turnaround time for testing outcomes. Furthermore, the cost of pharmacogenehc testing ranges from 8250-$500. While testmg required by
the FDA 1s usually reimbursed by third-party payers, add1t10nal testing
beyond what is required by the FDA must be supported by high-quality
evidence of clinical value before reimbursement and coverage are considereu. Although UriS evldem,-e miiy oo ro1t11co n1ir1y, it is :>till uncertain rr
all third-party payers will reimburse for such testing.13
Unfortunately, even if all of the above concerns were overcome,
further difficulties may lie ahead. Interpretation of pharmacogenetic tests
is particularly important due to their influence on the dosing of drugs. To
do this requires knowledge about genetic and nongenetic factors that
affect drug disposition and pharmacodynamics. 12 Introduction of these
factors into practice will undoubtedly complicate the process of prescribing and dispensing drugs. When only one or iwo approved drugs are
available for a given condition, and genetic variations prevent patients
from using them, patients may be left with no alternatives for treatment
Furthermore, drug manufacturers may be unwilling to put forth the llme
and effort to develop multiple pharmacogenomic products due to the
cost of bnngrng a drug to market 11
Ethical issues in pharmacogenomics
Several concerns ex1St surrounding etl1ical issues. The biggest fear for
patients related to genetic testing 1s potential discrimination in health
insurance and employment Some people worry that after undergoing certain genetic testing, informotion concerning any current health
problems, along with health problems that will arise in the future, will
not be held completely confidential. Because of this, many patients may
refuse available genetic testing, thereby sacrificing improvements in their
therapy. The message that must be sent to these patients 1s that genetic
testing for enhancement in drug trerapy involves the testing of only
certain enzymes or other proteins that are related to a specific therapy,
and the results are part of private medical records. 14 A person's genetic
lnformatton is protected through t~e Health Insurance Portabillty and Accountability Act (HIPAA), which was passed by Congress in 1996. Many
states also have laws 1n place that protect the privacy of health information, including genetic data.
Another ethical quesaon involves the allocation of human resources.
Some suggest that rather than focus on how genes indicate a pred1Spos1tion to dJSease or expenment with ways to change the human germ cell,
efforts should oo put forth to solve more urgent problems such as worldwide famine or water access. On the other side of t11e argument are those
that speak for the 100,000 hospital zed patients that die annually due to
adverse drug reactions and the additional 2.2 million patients that endure
non-fatal but serious reactions.15 can the obligation of a physician put forth
by the Hippocraoc Oath oo upheld when the information currently available about how drugs will affect specific patients is currently inadequate?
Another ethical concern mlates to tile distribution of burdens and benefits
involved in the development of the field. The cost of gene-guided therapy
will determine who will have access. and a desire for financial gain among
researchers could overpower an m:erest in either achieving valid data or
protecting the well-being of subpcts. Also, ga1nmg genebc mformat10n for
the benefit of a paoent may sornebmes require access to family health ur
formation If family memoorn refuse to release such information, d1fhculttes
in patient treatment may be encountered. 16
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The pharmacist's role in pharmacogenomics
Given the co11ect1on of obStacles discussed, add1t1ona1 work must be
accomplished before pharmacogenom1c discoveries will hnd extensive
chmcal application. First is the need for add1t1onal research. Randomized
chmcal tnals must be performed to evaluate the efficacy in unprovemeni
of clinical outcomes. Although testmg may help mform clinical decJSions,
ove1all patieut benefit 1mu cusl effectlve11ess have yet to be fully ueLe1mined. Additionally few guidelines exist addressmg the use of partlCular
pharmacogenetic tests, and providers must be educated about pharmacogemoics before we can see its full potential impact to treatment The
rapid changes in this field may result in a provider population that may
not feel confident interpreting genetic tests and counseling patients on
results. At this time, many researchers in the scientific community are
looking to pharmacists as the leaders forthe emergence of this new field
mro clmical practice. With their vast knowledge and understandmg of
phanmacoklnehcs and pharmacodynamics, pharmacists are expected
to play a key role in applying pharmacogenomtc discovenes to patient
care.•z
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